Personalis Awards 100,000 Stock Options to New VP Corporate Controller

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Very Positive)

Tags

07/18/2025 - 04:00 PM

FREMONT, Calif.--(BUSINESS WIRE)-- (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on July 15, 2025, a non-qualified stock option to purchase an aggregate of 100,000 shares of its common stock to Personalis鈥� new Vice President, Corporate Controller under Personalis鈥� 2020 Inducement Plan.

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual鈥檚 entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Personalis is making this announcement as required by Nasdaq rules.

The inducement stock option granted on July 15, 2025 has an exercise price of $6.31 per share, which is equal to the closing price of Personalis鈥� common stock on the grant date. The inducement stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and 1/36th of the remaining shares vesting monthly thereafter, subject to continued service through each applicable vesting date. The foregoing inducement award is subject to the terms and conditions of Personalis鈥� 2020 Inducement Plan, and the terms and conditions of the applicable award agreement covering the grant.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on and .